Gemcitabine and docetaxel combination chemotherapy for advanced bone and soft tissue sarcomas: protocol for an open-label, non-randomised, Phase 2 study

BACKGROUND: The prognosis of patients with metastatic or advanced sarcomas is poor and there are few options for treatment. Several studies have shown that gemcitabine and docetaxel (GD) combination chemotherapy has antitumor activity against various subtypes of sarcoma. Recently, some studies have...

Descripción completa

Detalles Bibliográficos
Autores principales: Hara, Hitomi, Kawamoto, Teruya, Fukase, Naomasa, Kawakami, Yohei, Takemori, Toshiyuki, Fujiwara, Shuichi, Kitayama, Kazumichi, Nishida, Kotaro, Kuroda, Ryosuke, Akisue, Toshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6651911/
https://www.ncbi.nlm.nih.gov/pubmed/31337342
http://dx.doi.org/10.1186/s12885-019-5923-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6651911/
https://www.ncbi.nlm.nih.gov/pubmed/31337342
http://dx.doi.org/10.1186/s12885-019-5923-7

Ejemplares similares